193 related articles for article (PubMed ID: 35131871)
1. Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice.
Casado-García A; Isidro-Hernández M; Oak N; Mayado A; Mann-Ran C; Raboso-Gallego J; Alemán-Arteaga S; Buhles A; Sterker D; Sánchez EG; Martínez-Cano J; Blanco O; Orfao A; Alonso-López D; De Las Rivas J; Riesco S; Prieto-Matos P; González-Murillo Á; García Criado FJ; García Cenador MB; Radimerski T; Ramírez-Orellana M; Cobaleda C; Yang JJ; Vicente-Dueñas C; Weiss A; Nichols KE; Sánchez-García I
Cancer Res; 2022 Mar; 82(6):1098-1109. PubMed ID: 35131871
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomics reveals multistep pathogenesis of E2A-PBX1 acute lymphoblastic leukemia.
Duque-Afonso J; Feng J; Scherer F; Lin CH; Wong SH; Wang Z; Iwasaki M; Cleary ML
J Clin Invest; 2015 Sep; 125(9):3667-80. PubMed ID: 26301816
[TBL] [Abstract][Full Text] [Related]
4. A robust in vivo model for B cell precursor acute lymphoblastic leukemia.
Fry TJ; Aplan PD
J Clin Invest; 2015 Sep; 125(9):3427-9. PubMed ID: 26301807
[TBL] [Abstract][Full Text] [Related]
5. Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility.
Martín-Lorenzo A; Hauer J; Vicente-Dueñas C; Auer F; González-Herrero I; García-Ramírez I; Ginzel S; Thiele R; Constantinescu SN; Bartenhagen C; Dugas M; Gombert M; Schäfer D; Blanco O; Mayado A; Orfao A; Alonso-López D; Rivas Jde L; Cobaleda C; García-Cenador MB; García-Criado FJ; Sánchez-García I; Borkhardt A
Cancer Discov; 2015 Dec; 5(12):1328-43. PubMed ID: 26408659
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
7. EBF1-JAK2 inhibits the PAX5 function through physical interaction with PAX5 and kinase activity.
Kojima Y; Kawashima F; Yasuda T; Odaira K; Inagaki Y; Yamada C; Muraki A; Noura M; Okamoto S; Tamura S; Iwamoto E; Sanada M; Matsumura I; Miyazaki Y; Kojima T; Kiyoi H; Tsuzuki S; Hayakawa F
Int J Hematol; 2023 Jul; 118(1):65-74. PubMed ID: 37149540
[TBL] [Abstract][Full Text] [Related]
8. EBF1 and Pax5 safeguard leukemic transformation by limiting IL-7 signaling, Myc expression, and folate metabolism.
Ramamoorthy S; Kometani K; Herman JS; Bayer M; Boller S; Edwards-Hicks J; Ramachandran H; Li R; Klein-Geltink R; Pearce EL; Grün D; Grosschedl R
Genes Dev; 2020 Nov; 34(21-22):1503-1519. PubMed ID: 33004416
[No Abstract] [Full Text] [Related]
9. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.
Schinnerl D; Fortschegger K; Kauer M; Marchante JR; Kofler R; Den Boer ML; Strehl S
Blood; 2015 Feb; 125(8):1282-91. PubMed ID: 25515960
[TBL] [Abstract][Full Text] [Related]
10. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia.
Liu GJ; Cimmino L; Jude JG; Hu Y; Witkowski MT; McKenzie MD; Kartal-Kaess M; Best SA; Tuohey L; Liao Y; Shi W; Mullighan CG; Farrar MA; Nutt SL; Smyth GK; Zuber J; Dickins RA
Genes Dev; 2014 Jun; 28(12):1337-50. PubMed ID: 24939936
[TBL] [Abstract][Full Text] [Related]
11. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
12. PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice.
Jamrog L; Chemin G; Fregona V; Coster L; Pasquet M; Oudinet C; Rouquié N; Prade N; Lagarde S; Cresson C; Hébrard S; Nguyen Huu NS; Bousquet M; Quelen C; Brousset P; Mancini SJC; Delabesse E; Khamlichi AA; Gerby B; Broccardo C
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10357-10362. PubMed ID: 30257940
[No Abstract] [Full Text] [Related]
13. Identification of mutations that cooperate with defects in B cell transcription factors to initiate leukemia.
Heltemes-Harris LM; Hubbard GK; LaRue RS; Munro SA; Yang R; Henzler CM; Starr TK; Sarver AL; Kornblau SM; Farrar MA
Oncogene; 2021 Oct; 40(43):6166-6179. PubMed ID: 34535769
[TBL] [Abstract][Full Text] [Related]
14. PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.
Dang J; Wei L; de Ridder J; Su X; Rust AG; Roberts KG; Payne-Turner D; Cheng J; Ma J; Qu C; Wu G; Song G; Huether RG; Schulman B; Janke L; Zhang J; Downing JR; van der Weyden L; Adams DJ; Mullighan CG
Blood; 2015 Jun; 125(23):3609-17. PubMed ID: 25855603
[TBL] [Abstract][Full Text] [Related]
15. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia.
Nebral K; Denk D; Attarbaschi A; König M; Mann G; Haas OA; Strehl S
Leukemia; 2009 Jan; 23(1):134-43. PubMed ID: 19020546
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis.
Isidro-Hernández M; Mayado A; Casado-García A; Martínez-Cano J; Palmi C; Fazio G; Orfao A; Ribera J; Ribera JM; Zamora L; Raboso-Gallego J; Blanco O; Alonso-López D; De Las Rivas J; Jiménez R; García Criado FJ; García Cenador MB; Ramírez-Orellana M; Cazzaniga G; Cobaleda C; Vicente-Dueñas C; Sánchez-García I
Sci Rep; 2020 Nov; 10(1):19189. PubMed ID: 33154497
[TBL] [Abstract][Full Text] [Related]
17. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
18. Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.
Hart MR; Anderson DJ; Porter CC; Neff T; Levin M; Horwitz MS
PLoS Genet; 2018 Sep; 14(9):e1007642. PubMed ID: 30216339
[TBL] [Abstract][Full Text] [Related]
19. The JAK3
Lahera A; Vela-Martín L; Fernández-Navarro P; Llamas P; López-Lorenzo JL; Cornago J; Santos J; Fernández-Piqueras J; Villa-Morales M
Mol Carcinog; 2024 Jan; 63(1):5-10. PubMed ID: 37712558
[TBL] [Abstract][Full Text] [Related]
20. B Cell Linker Protein (BLNK) Is a Selective Target of Repression by PAX5-PML Protein in the Differentiation Block That Leads to the Development of Acute Lymphoblastic Leukemia.
Imoto N; Hayakawa F; Kurahashi S; Morishita T; Kojima Y; Yasuda T; Sugimoto K; Tsuzuki S; Naoe T; Kiyoi H
J Biol Chem; 2016 Feb; 291(9):4723-31. PubMed ID: 26703467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
